Search clinical trials for: Fruquintinib plus Chemotherapy

Total 24162 results

Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients

Chemotherapy | Leukemia, Acute Lymphoblastic

Italy
Sun Yat-sen University

Recruiting

Deferoxamine Plus Chemotherapy for Metastatic Triple Negative Breast Cancer

Triple Negative Breast Cancer

China
Hunan Province Tumor Hospital

Recruiting

Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC

Non Small Cell Lung Cancer

China
Hunan Province Tumor Hospital

Recruiting

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer (Awesome)

Non Small Cell Lung Cancer

China
Cancer Institute and Hospital, Chinese Academy...

Recruiting

FMT Combined With Immune Checkpoint Inhibitor and TKI in the Treatment of CRC Patients With Advanced Stage

Colorectal Neoplasms Malignant

China
Hunan Province Tumor Hospital

Recruiting

Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK (BEYOND)

Lung Adenocarcinoma | ALK Gene Mutation | Immunotherapy

China
Elizabeth Dudnik

Recruiting

Durvalumab (MEDI4736) Plus Platinum-based Chemotherapy in Advanced LCNEC: a Pilot Phase II Study

Patients With Advanced Treatment Naive LCNEC

Israel
AstraZeneca

Recruiting

Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment (SAFFRON)

Carcinoma | Non-Small-Cell Lung

China, Israel, Spain, United States, Canada, Italy, Korea, Republic of, Belgium, Bulgaria, Vietnam, Japan, United Kingdom, Brazil, France, Philippines, Taiwan, Thailand, Germany, Poland, Austria, Greece, Turkey, Malaysia, Argentina, Hong... and more
Ruijin Hospital
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Anlotinib Plus Chemotherapy as First-line Therapy for Gastrointestinal Tumor Patients With Unresectable Liver Metastasis (ALTER-G-001) (ALTER-G-001)

Gastrointestinal Tumors

China
Seoul National University Hospital
Focused Ultrasound Foundation; Synex Consulting Ltd

Recruiting

Concurrent FOLFIRINOX Plus High Intensity Focused Ultrasound for Pancreatic Cancer

Chemotherapy Effect | Pancreatic Cancer Non-resectable | Ultrasound Therapy

Korea, Republic of
National Cancer Institute (NCI)
NRG Oncology

Recruiting

Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

Endometrial Serous Adenocarcinoma | Uterine Corpus Carcinosarcoma

United States, Puerto Rico
Georgetown University

Recruiting

RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer (RAGE)

Non-metastatic Breast Cancer | Cancer Related Cognitive Decline

United States
Shengjing Hospital

Not yet recruiting

Chidamide Combined With Exemestane (+/- Goserelin) Versus Neoadjuvant Chemotherapy in Patients of Stage II-III HR-positive/HER2-negative Breast Cancer

Breast Neoplasms
Rockefeller University
National Institute of Allergy and Infectious Diseases (NIAID); University of... and other collaborators

Recruiting

3BNC117-LS and 10-1074-LS Plus N-803 (bNAb+N-803)

Human Immunodeficiency Virus

United States
Sichuan Cancer Hospital and Research Institute
The First Affiliated Hospital with Nanjing Medical University; Peking University... and other collaborators

Not yet recruiting

Sintilimab Plus NCT or NCRT Versus NCRT for ESCC

Esophageal Squamous Cell Carcinoma

China
Wei Xu

Recruiting

Tislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary

Chemotherapy Effect | Gene Mutation-Related Cancer | Tislelizumab | Cancer of Unknown Primary | Bone Cancer Metastatic | Immune Evasion, Tumor

China
Tianjin Medical University Cancer Institute and...

Recruiting

Conversion Therapy of Hyperthermic Intraperitoneal Chemotherapy Plus Chemotherapy and Chemotherapy in Stage IV Gastric Cancer

Gastric Cancer

China
Norwegian University of Science and Technology
Karolinska University Hospital; Oslo University Hospital; University Hospital... and other collaborators

Recruiting

Chemo-immunotherapy Plus Thoracic Radiotherapy in Extensive Stage Small-cell Lung Cancer (TRIPLEX)

Small-cell Lung Cancer

Netherlands, Norway, Sweden, Estonia, Iceland
Jiuda Zhao
Second Hospital of Lanzhou University

Recruiting

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

Gastric Cancer | Chemotherapy | Immunotherapy

China
Shanghai Zhongshan Hospital
Bristol-Myers Squibb

Recruiting

Study of Neoadjuvant Nivolumab or Placebo Plus Chemotherapy Followed by Surgery and Adjuvant Treatment in Subjects With Resectable ESCC

Esophageal Squamous Cell Carcinoma

China
Nanfang Hospital of Southern Medical University

Recruiting

Penpulimab Plus Chemotherapy With/Without Anlotinib for Patients With Advanced Esophageal Squamous Cell Carcinoma (ANSWER)

Essential Tremor

China
Sun Yat-sen University

Recruiting

Tislelizumab Plus Chemotherapy as First-Line Treatment for Advanced Squamous NSCLC With Brain Metastases

Brain Metastases | Non-Small Cell Squamous Lung Cancer

China
The First Affiliated Hospital of Henan University...

Not yet recruiting

Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC

NSCLC
Ruijin Hospital

Recruiting

Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis

Peritoneal Metastases | Gastric Cancer Stage IV

China
Sun Yat-sen University

Recruiting

Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial

Hepatocellular Carcinoma

China
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Non Small Cell Lung Cancer | ALK Gene Mutation

France
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Lung Adenocarcinoma | Stage III Lung Cancer AJCC v8 | Lung Non-Squamous Non-Small Cell Carcinoma | Lung Large Cell Carcinoma

United States
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Recruiting

A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102 (Bevacizumab) as First-line Treatment in Cervical Cancer

Cervical Cancer

China
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer

Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Hypopharyngeal Carcinoma AJCC v8 | Stage III Laryngeal Cancer AJCC v8 | Stage III Lip and Oral Cavity Cancer AJCC v8 | Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8 | Stage IVA Lip and Oral... and other conditions

United States, Canada
Peking Union Medical College Hospital

Recruiting

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma.

Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC

China
Fudan University

Recruiting

The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Pancreatic Cancer

China
Bristol-Myers Squibb

Recruiting

A Study of Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer (INGA)

Gastric Cancer

Germany
Jazz Pharmaceuticals
BeiGene, Ltd.

Recruiting

A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers (HERIZON-GEA-01)

Gastroesophageal Adenocarcinoma | Esophageal Adenocarcinoma | Gastric Neoplasms

Korea, Republic of, Belgium, Japan, China, Netherlands, Spain, Germany, United Kingdom, Malaysia, Portugal, France, Italy, Australia, Taiwan, Turkey, Thailand, Argentina, Mexico, Ireland, Estonia, Serbia, Romania, Canada, Poland, Brazil, ... and more
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China
M.D. Anderson Cancer Center
AstraZeneca

Recruiting

A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder

Bladder Cancer | Urothelial Carcinoma

United States
Fudan University

Not yet recruiting

A Study of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

Metastatic Pancreatic Cancer

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Not yet recruiting

A Study of SHR-1701 Plus Bevacizumab and Chemotherapy in Non-Small-Cell-Lung-Cancer

Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer
Guangxi Medical University

Recruiting

Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma

Gastric Cancer | GastroEsophageal Cancer | Fruquintinib | SOX

China
Sun Yat-sen University

Recruiting

Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer

Breast Cancer

China
Sun Yat-sen University

Recruiting

Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses

Paranasal Sinus Cancer | Induction Chemotherapy | Camrelizumab | Nasal Cavity Cancer | Intensity Modulated Radiotherapy | Concurrent Chemotherapy

China
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3

China
Fudan University

Not yet recruiting

Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Neoplasms | Gastroesophageal Junction Adenocarcinoma

China
Amgen

Recruiting

Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer (FORTITUDE-102)

Gastric Cancer | Gastroesophageal Junction Adenocarcinoma

Korea, Republic of, China, United States, Israel, Italy, Spain, Switzerland, Canada, Australia, Germany, United Kingdom, Austria, France, Japan, Taiwan, Belgium, Poland, Thailand, Czechia, Singapore, Hungary, Argentina, Brazil, Romania, Portuga... and more
Aiping Shi

Recruiting

Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer

Triple Negative Breast Cancer (TNBC)

China
National Cancer Institute (NCI)

Recruiting

Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers

Recurrent Head and Neck Squamous Cell Carcinoma | Recurrent Hypopharyngeal Squamous Cell Carcinoma | Recurrent Laryngeal Squamous Cell Carcinoma | Metastatic Head and Neck Squamous Cell Carcinoma | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage IV Hypopharyngeal... and other conditions

United States
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine Carcinoma

United States
M.D. Anderson Cancer Center

Recruiting

Tagraxofusp and Low-Intensity Chemotherapy for the Treatment of CD123 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

Recurrent Adult Lymphoblastic Lymphoma | Recurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory T Acute Lymphoblastic Leukemia | Recurrent T Acute Lymphoblastic Leukemia | Refractory Lymphoblastic Lymphoma

United States
Wan He

Recruiting

PD-1 Blockade With JS001 Plus Neoadjuvant Chemotherapy for Gastric/Gastroesophageal Junction Cancer (PNACGEC)

Stomach Neoplasms

China
First Affiliated Hospital Xi'an Jiaotong University

Recruiting

A Study of Dasatinib Plus Reduced Intensive Consolidation Chemotherapy in Ph+ Adult ALL

Precursor Cell Lymphoblastic Leukemia-Lymphoma | ALL, Adult | Philadelphia-Positive Acute Lymphoblastic Leukemia

China
Peking University Cancer Hospital & Institute

Not yet recruiting

cTACE or DEB-TACE+HAIC Combined With Regorafenib ± Anti-PD1 Antibody for uHCC

HCC | Regorafenib | Transarterial Chemoembolization | Hepatic Arterial Infusion Chemotherapy

Search clinical trials for: Fruquintinib plus Chemotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations